NLS Pharmaceutics AG
NASDAQ:NLSP
NLS Pharmaceutics AG
Research & Development
NLS Pharmaceutics AG
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
NLS Pharmaceutics AG
NASDAQ:NLSP
|
Research & Development
-$422.1k
|
CAGR 3-Years
59%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Novartis AG
SIX:NOVN
|
Research & Development
-$10.3B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-2%
|
|
|
Roche Holding AG
SIX:ROG
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
O
|
Oculis Holding AG
NASDAQ:OCS
|
Research & Development
-CHf18.8m
|
CAGR 3-Years
-60%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sandoz Group AG
SIX:SDZ
|
Research & Development
-$1B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
NLS Pharmaceutics AG
Glance View
NLS Pharmaceutics Ltd. engages in the discovery and development of drug therapies to treat rare and complex central nervous systems disorders, including narcolepsy, idiopathic hypersomnia and other rare sleep disorders, and of neurodevelopmental disorders, such as Attention Deficit Hyperactivity Disorder. The company is headquartered in Stans, Nidwalden and currently employs 6 full-time employees. The firm focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The firm serves customers worldwide.
See Also
What is NLS Pharmaceutics AG's Research & Development?
Research & Development
-422.1k
USD
Based on the financial report for Dec 31, 2024, NLS Pharmaceutics AG's Research & Development amounts to -422.1k USD.
What is NLS Pharmaceutics AG's Research & Development growth rate?
Research & Development CAGR 5Y
24%
Over the last year, the Research & Development growth was 93%. The average annual Research & Development growth rates for NLS Pharmaceutics AG have been 59% over the past three years , 24% over the past five years .
